MedWatch

Increased FDA demands affect Neurosearch-rights

Neurosearch is prepared to give up on the European rights for Huntexil in the search of a partner to finance a new phase III-study.

Foto: Jyllands-Posten

It will be more costly than previously expected for the Danish biotech company Neurosearch, if they are to succeed in securing a partner for the completion of clinical trials of the company’s Huntingtons medicine, Huntexil, according to a stock exchange release from the company.

In its yearly financial statement the biotech company already announced that either a capital expansion or a financial partner for the phase-III-trials with Huntexil would be necessary, and that the current capital would only last until 2013 – and that’s still the case.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier